الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Anogenital warts (AGW) are the most common sexually transmitted disease. AGW are caused by several genotypes of human papilloma virus (HPV) that affect the anogenital region of both women and men.
Choosing a treatment method for anogenital warts depend on their anatomic location, extent and size of the lesions, effectiveness of previous treatments, accompanying conditions (pregnancy, immunosuppression), the patient’s preferences, treatment adherence, expectations and treatment cost. Treatment must be individualized for each patient. The treatment of anogenital warts is classified into three categories: topical cytotoxic, immunotherapeutic, and destructive therapies.
Intralesional immunotherapy has recently gained popularity in the treatment of warts.
Macrophage migration inhibitory factor (MIF) can regulate innate and adaptive immunity. MIF is believed to be a criminal agent in many diseases such as allergic and irritant contact dermatitis, atopic dermatitis, psoriasis, vitiligo, alopecia areata, pemphigus vulgaris, and bullous pemphigoid.
The aim of this study is to evaluate the serum level of macrophage migration inhibitory factor in patients with external ano-genital warts before and after intra-lesional purified protein derivative (PPD) injection.
This study included 40 patients with external anogenital warts and was conducted at the dermatology clinic and the andrology, infertility and sexually transmitted diseases clinic, Suez Canal University Hospital in Ismailia. All patients were injected 10 TU of tuberculin PPD intra